Log In Get Started
Press Releases March 26, 2026 08:33 AM

Golar LNG Limited - Announcement of filing of Form 20-F Annual Report

Golar LNG Limited Files Form 20-F Annual Report for 2025

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
GLNG

Golar LNG Limited has filed its Form 20-F annual report for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission, making the report available for shareholders and public access.

Golar LNG Limited - Announcement of filing of Form 20-F Annual Report
GLNG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Form 20-F for 2025 was filed with the SEC as required for foreign private issuers listed in the U.S.
  • The report is accessible on Golar LNG's website and shareholders can request a hard copy free of charge.
  • The disclosure complies with Norwegian Securities Trading Act requirements.

Golar LNG Limited announces that it has filed its Form 20-F for the year ended December 31, 2025, with the Securities and Exchange Commission in the U.S.

Form 20-F can be downloaded from the link below, is available on our website www.golarlng.com and shareholders may receive a hard copy free of charge upon request. 

March 26, 2026
The Board of Directors
Hamilton, Bermuda

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act


Risks

  • Market reaction to annual reports can vary based on financial performance details within the filing, which are not detailed here.
  • The LNG sector is exposed to fluctuating global energy prices and regulatory changes affecting demand and supply.
  • Geopolitical risks and shipping industry factors could impact Golar LNG's business prospects.

More from Press Releases

Silvaco CEO Dr. Walden “Wally” Rhines Inducted into the National Academy of Engineering Oct 2, 2026 Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) Oct 2, 2026 Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 Oct 1, 2026 New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program Oct 1, 2026 FEMSA Schedules Conference Call to Discuss Third Quarter Financial Results Oct 1, 2026